CD34 and neoplasm: Angiogenesis also decreased in vivo according to the immunohistochemical assessment of the mouse xenograft tumor samples when injected with Ad-ING4: Tumor blood vessel expression of the hematopoietic stem cell marker CD34 was weaker, or observed in fewer cells overall, in the ING4 treated cells in comparison to the untreated control tumors.